Metabolic Syndrome Management

Introduction to Retatrutide

Retatrutide, a triple-hormone receptor agonist (GLP-1, GIP, and glucagon), may help reduce visceral adipose tissue, which is strongly associated with metabolic syndrome, and demonstrates substantial weight reduction benefits and glycemic control, according to the Journal of Hepatology 1, 2
The mechanism of retatrutide produces several effects, including potentiation of insulin secretion, inhibition of appetite and increase in satiety, and increase in lipolysis, lipid oxidation, and energy expenditure 1

Adults with obesity (BMI ≥30 kg/m²) or overweight (BMI 27-29.9 kg/m²) with at least one weight-related comorbidity, and patients with type 2 diabetes who have not achieved glycemic targets with first-line treatments, may benefit from retatrutide, as suggested by the EASL-EASD-EASO clinical practice guidelines 1, 3
Middle-aged and postmenopausal women with higher rates of obesity may also benefit from retatrutide 3

Substantial weight loss induced by GLP-1 receptor agonists, including triple agonists like retatrutide, could provide hepatic histological benefit for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), according to the EASL-EASD-EASO clinical practice guidelines 1
Phase 3 trials are ongoing to further establish the efficacy and safety of retatrutide, and potential combination therapies with lipogenesis inhibitors may provide additional benefits 1
Long-term cardiovascular outcome trials are needed to assess the impact of retatrutide on major adverse cardiovascular events 1

Limited insurance coverage and socioeconomic disparities in access to obesity medications exist, with 11.9% of eligible adults being uninsured and 33.6% having low income, which disproportionately affects low-SES groups 3